General (147) Partnerships (40) New Products (8) Acquisitions (6) New Technologies (4) Financials (3)
Pharma and Biotech (162) Corporate (20) Bioscience (8)
2021 (3) 2020 (42) 2019 (29) 2018 (23) 2017 (21) 2016 (26) 2015 (12) 2014 (6)
English (162)
EnglishX
Showing 41‐60 of 162
results per page
09 Mar 2020
Lonza Collaborates with Immunotherapy Leaders to Assess Point-of-Care Manufacturing for Cancer Cell Therapies
Research collaboration with leading research institutes and academic clinical centers Stanford University School of Medicine, Fred Hutchinson...
19 Feb 2020
Lonza confirms COVID-19 case at Singapore General Office
Basel, Switzerland, 19 February 2020 –A Singapore-based employee of Lonza is being treated for a confirmed cased of COVID-19 (Coronavirus).Albert...
28 Jan 2020
Lonza Supporting Rocket Pharma with Clinical Manufacturing of LAD-I for the Treatment of Leukocyte Adhesion Deficiency-I
Clinical manufacturing to be carried out at Lonza's Houston (TX), USA and Geleen, Netherlands cGMP manufacturing sites for supply in the USA and in...
10 Jan 2020
Indapta Therapeutics and Lonza Announce Strategic Partnership to Advance a Next-generation, Off-the-shelf, Allogeneic Immuno-oncology Therapy
•  Indapta developing first-in-class, proprietary cancer therapy based on a specific, potent variety of Natural Killer immune cells for use in...
09 Jan 2020
Lukas Schüpbach appointed CEO of Bacthera
Chr. Hansen and Lonza’s 50/50 joint venture for Live Biotherapeutic Products (LBP), Bacthera, announces Lukas Schüpbach as the company’s CEOBasel,...
19 Dec 2019
Lonza and Allevi Collaborate to Advance 3D Bioprinting
Collaboration brings technology and consumables together for bioprinting for research applications.Lonza brings a broad range of high-quality...
26 Nov 2019
Lonza and DiNAQOR AG Announce Strategic Collaboration to Advance Gene Therapy Programs for Patients with Monogenic Cardiomyopathies
Strategic collaboration to focus on DiNAQOR’s adeno-associated virus gene therapy production systemCompanies to partner on gene therapy process and...
13 Nov 2019
Lonza’s New eCHO™ Basal Medium and Feed Facilitates Late-Stage Cell Viability and a Consistent Yield of High Integrity Proteins
Lonza has launched a new basal and feed medium, specifically developed to drive significant viability and integrity enhancements in protein...
05 Nov 2019
Lonza Partners with Cryoport and Strengthens its 'Vein-to-vein' Delivery Network in Cell & Gene Therapy
Cryoport as a preferred partner for Lonza in the transport and delivery of patient tissues on a global basisPartnership incorporates Cryoport’s...
16 Oct 2019
Mesoblast and Lonza Enter into Agreement for Commercial Manufacture of Mesoblast’s Potential First United States Allogeneic Therapy
Quote from Alberto Santagostino, SVP Head of Cell & Gene Technologies, Lonza:“Mesoblast is a true trailblazer, leading the way in developing...
14 Oct 2019
Lonza’s Ibex™ Solutions to Support Genmab’s Growing Clinical Portfolio
Lonza’s Ibex™ Design planned to take Genmab’s pre-clinical candidates from gene to potential IND within 12 monthsLonza’s Ibex™ Develop will enable...
01 Oct 2019
Cellectis and Lonza Enter cGMP Manufacturing Service Agreement for Cellectis’ Allogeneic UCART Product Candidates
Agreement covers manufacturing of clinical supply for Cellectis’ UCART pipelineManufacturing to take place at Lonza’s GMP site in Geleen,...
09 Sep 2019
Citryll and Lonza Enter Into Partnership to Manufacture NETosis Inhibiting Antibody CIT-013
•  Citryll’s CIT-013 could offer new treatment options for various human diseases including lupus, vasculitis, pulmonary fibrosis and organ damage...
03 Sep 2019
Celltrion and Lonza Sign Contract to Manufacture Remsima Drug Substance
•  Celltrion contracts Remsima drug substance manufacturing to Lonza to satisfy increasing global demand for biosimilars•  Lonza’s biologics...
29 Aug 2019
Chr. Hansen and Lonza’s newly branded joint venture, BacThera, receives anti-trust approvals to start contract manufacturing of live biotherapeutic products
Copenhagen, Denmark and Basel, Switzerland, 29 August 2019 – Chr. Hansen Holding A/S, a leading global bioscience company, and Lonza AG, a leading...
31 Jul 2019
Omeros and Lonza Enter Long-Term Manufacturing Agreement for Commercial Supply of Narsoplimab
Seattle, USA and Basel, Switzerland, 31 July 2019 – Omeros Corporation (Nasdaq: OMER) and Lonza (SWX: LONN) today announced a long-term...
30 Jul 2019
Lonza Partners with Vineti Across its Cell and Gene Therapy Manufacturing Network to Optimize 'Vein-to-Vein' Delivery Service
Vineti and Lonza as preferred partners, respectively for patient tissue tracking and contract development and manufacturing services in cell and...
24 Jul 2019
Lonza Expands Bioconjugation Facility and Announces Approval of Third Commercial ADC
•  Expansion to bioconjugation facility in Visp, Switzerland to meet increasing clinical, launch and commercial market demand•  Facility recently...
09 Jul 2019
Extensive expansion at Lonza’s Tampa site provides streamlined services for solid oral dosage forms
Development: New product development suites inclusive of expanded powder-in-capsule / powder-in-bottle micro-dosing capacity for early-phase...
01 Jul 2019
Lonza to Acquire Sterile Fill and Finish F acility from Novartis
Facility in Stein (CH) will complement Lonza Pharma & Biotech’s current parenteral drug product offering in Basel (CH) First facility for...
< 1 2 3 4 5 6 ... 9 >